InvestorsHub Logo
Followers 35
Posts 2513
Boards Moderated 0
Alias Born 01/02/2003

Re: flipper44 post# 685470

Tuesday, 04/16/2024 1:20:36 PM

Tuesday, April 16, 2024 1:20:36 PM

Post# of 695565
Flip I had that question your post makes sense. I’m also assuming there are adjustments from NICE annually either on a CY or fiscal year consistent with the NICE decision date. Plus, there should be reimbursement adjustments annually to account for inflation and NICE budget variances.

Does it make sense to you that Oncovir would mirror L applications in the UK and other jurisdictions for GBM?
It makes sense to me as additional approvals for Poly/GBM obviously enhance Oncovir enterprise value vs Poly revenue as off label for Oncovir. If that’s true then Oncovir can use MHRA accelerated pathways since already approved by FDA.
Would we not see Oncovir and Poly when searching MHRA website?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News